Development and strategies of VEGFR-2/KDR inhibitors. - Wikidata - wikimedia - TriplyDB

Development and strategies of VEGFR-2/KDR inhibitors.

Development and strategies of VEGFR-2/KDR inhibitors.

http://www.wikidata.org/entity/Q34436101

about

Discovery of a New Series of Naphthamides as Potent VEGFR-2 Kinase Inhibitors Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy.Altered expression profile of apoptosis-related molecules correlated with clinicopathological factors in non-small-cell lung cancer.Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors Discovery of multi-target receptor tyrosine kinase inhibitors as novel anti-angiogenesis agents.VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Fragment virtual screening based on Bayesian categorization for discovering novel VEGFR-2 scaffolds.

P2860

Q33636113-C5ABB0C6-3CAB-43DB-AF74-178C9C6334F6 Q36212825-1161C509-4528-44F4-B894-C805BC950282 Q36261752-88E271B6-89C9-47C5-94DA-8C763EEDD920 Q37311579-ECE932AD-2347-4DCD-842E-1FEBDD89C855 Q37717135-BC0A8732-8D1C-4C5F-8BB6-7E0B5F9D01AA Q39378135-1536235F-B4A7-4B94-9B12-E827507452F7 Q50907163-B22DD75D-0442-403D-943F-81EA87E96589

P2860

Development and strategies of VEGFR-2/KDR inhibitors.

http://www.wikidata.org/entity/Q34436101

description

2012 nî lūn-bûn

@nan

2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Development and strategies of VEGFR-2/KDR inhibitors.

@ast

Development and strategies of VEGFR-2/KDR inhibitors.

@en

Development and strategies of VEGFR-2/KDR inhibitors.

@nl

type

label

Development and strategies of VEGFR-2/KDR inhibitors.

@ast

Development and strategies of VEGFR-2/KDR inhibitors.

@en

Development and strategies of VEGFR-2/KDR inhibitors.

@nl

prefLabel

Development and strategies of VEGFR-2/KDR inhibitors.

@ast

Development and strategies of VEGFR-2/KDR inhibitors.

@en

Development and strategies of VEGFR-2/KDR inhibitors.

@nl

P1433

Q34436101-9585FA63-B371-43B7-A63C-D16DCC8AB58B

P1476

Q34436101-4F4EF49A-F37A-400B-AEC6-A7D82C22AF43

P2093

Q34436101-5CF54C42-928E-4D98-A8A7-876DFBDD7F64

Q34436101-5D3F439F-C266-47A2-955A-1C53286958D7

Q34436101-71C7BA2E-1BF2-4E07-ADE5-6E1F40FC4446

Q34436101-9C53994F-1980-415B-AC1C-DE5760517856

Q34436101-B47B46D4-C02A-47E5-B44E-4D257832965F

Q34436101-F9C2D369-B03D-4715-A3E5-79C9E25ED635

P2860

Q34436101-11C53B77-533A-4F3A-9406-9B8DBACD02C2

Q34436101-1339DFBD-F267-40A5-A4D3-61C216E18FC4

Q34436101-1C5BB06D-474E-427A-82D8-1ABBCFB5E117

Q34436101-1FE3FDED-87BA-4E2E-8986-9E8415840BF7

Q34436101-21F9E579-4BCC-4D0F-B7F8-BA21D5B09F07

Q34436101-279665D6-2B7D-434E-ABD7-649D93161C8C

Q34436101-27AB25A6-3ADF-4C2E-857E-F9A262E9D054

Q34436101-2BD71E0B-56C7-4358-A233-5672E98DD36F

Q34436101-307631DE-6485-45BF-92C0-E8419A38553A

Q34436101-366E2DD7-774E-4464-9275-372C200226D1

P304

Q34436101-E5A39EFE-2582-4A7D-9C26-164C5909569F

P31

Q34436101-ED31669C-CA15-4FA0-AB9C-72672DEF713E

P356

Q34436101-1DD78449-FFEA-4AA8-AB40-4F1840180210

P433

Q34436101-FA4BC8C9-BCEB-41F8-95AB-D5F0986F20EB

P478

Q34436101-A78FC291-1A88-4F62-80C8-81F8322CC717

P577

Q34436101-7A062FD0-AF64-4B7F-954E-BE3084DD030D

P698

Q34436101-DCCF3F34-C8D8-419D-9662-19EB4CC6170C

P356

P1433

Future Medicinal Chemistry

P1476

Development and strategies of VEGFR-2/KDR inhibitors.

@en

P2093

Kejiang Lin

http://www.w3.org/2001/XMLSchema#string

Lingyi Huang

http://www.w3.org/2001/XMLSchema#string

Liping Sun

http://www.w3.org/2001/XMLSchema#string

Rui Xie

http://www.w3.org/2001/XMLSchema#string

Zhengui Huang

http://www.w3.org/2001/XMLSchema#string

Zhiqiang Bai

http://www.w3.org/2001/XMLSchema#string

P2860

Vascular endothelial growth factor receptor KDR tyrosine kinase activity is increased by autophosphorylation of two activation loop tyrosine residues

The protein kinase complement of the human genome

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease

Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase

Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site

Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine Tie-2 kinase inhibitor

Structural factors contributing to the Abl/Lyn dual inhibitory activity of 3-substituted benzamide derivatives

Discovery of novel benzimidazoles as potent inhibitors of TIE-2 and VEGFR-2 tyrosine kinase receptors

P304

1839-1852

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4155/FMC.12.121

http://www.w3.org/2001/XMLSchema#string

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2012-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23043480

http://www.w3.org/2001/XMLSchema#string